key: cord-0740216-zoogbbzw
authors: Nuckchady, Dooshanveer C.
title: Hyperpyrexia and metabolic alkalosis in a COVID‐19 patient
date: 2020-07-08
journal: J Med Virol
DOI: 10.1002/jmv.26276
sha: 265ff6b51e3f7fcc4b0b33810473b075c6837d8c
doc_id: 740216
cord_uid: zoogbbzw

Hyperpyrexia can be a challenging and serious complication of SARS‐CoV‐2 infection. This article is protected by copyright. All rights reserved.

A 20-year-old girl with a past medical history of bronchial asthma was admitted at a healthcare facility in Mauritius with a three-day history of high-grade fever, cough and shortness of breath. On arrival, her oxygen saturation was 75% on room air, temperature was 42°C and respiratory rate was 35 per minute. Chest x-ray showed bilateral pulmonary infiltrates and a polymerase chain reaction test on a throat swab for SARS-CoV-2 was positive.

An arterial blood gas (ABG) on day 2 of admission revealed a mild respiratory acidosis with a pH of 7.30, pCO2 of 52 mmHg and a PaO2 of 34 mmHg while on a non-rebreather Accepted Article mask with oxygen flowing at 15 liters per minute. Thereafter, she was intubated. Her temperature varied from 42°C to 44°C.

On day 4 of her admission, a repeat ABG showed metabolic alkalosis with a pH of 7.55, pCO2 of 45 mmHg and a bicarbonate level of 38 mEq/L. Urea, creatinine, potassium and sodium levels were within normal range. She was treated with chloroquine, clarithromycin, normal saline, meropenem, methylprednisolone, paracetamol, and nebulized salbutamol with ipratropium. Unfortunately, she passed away on day 7.

Among intubated patients, post-hypercapneic metabolic alkalosis is often seen in the presence of chronic ventilatory defects like chronic obstructive pulmonary disease, obesity hypoventilation syndrome, cystic fibrosis, scoliosis or amyotrophic lateral sclerosis. However, this patient did not have such diseases; moreover, she was a non-smoker. She was believed to have a contraction alkalosis with loss of chloride ions because of dehydration due to an excessively elevated body temperature.

Jeong et al. published a case report about a 58-year-old woman with COVID-19 who presented with hyperpyrexia and recovered from a possible cytokine storm. 2 Soh et al. describe high grade fever with temperature above 40°C (without hyperpyrexia) in two COVID-19 patients who were treated with favipiravir and who developed neuroleptic malignant syndrome. 3 This is the first case report to confirm that hyperpyrexia can be seen in young adults infected by the SARS-CoV-2 virus.

Hyperpyrexia in COVID-19 patients

Therapeutic Temperature Modulation for a Critically Ill Patient with COVID-19

Neuroleptic malignant syndrome in patients with COVID-19